Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 65 years old~2. Asymptomatic hyperuricemia (sUA \> 6.0 mg/dL)~3. Body mass index between 18 and 35 kg/m2 inclusive and weight at least 50 kg and no more than 150 kg~4. Females must be non-pregnant, as well as post-menopausal or willing to use an acceptable method of contraception during the study.~Exclusion Criteria:~1. History of any clinically significant disease or disorder putting the patient at risk during the study, or influencing study results or ability to participate in the study~2. eGFR\* \< 45 mL/minute/1.73 m2 at Screening.~3. Type 2 diabetes mellitus with HbA1c \>8%.~4. History of diabetic ketoacidosis, hyperosmolar non-ketotic coma, gout, or alcohol or drug abuse.~5. Ongoing treatment with an SGLT2-inhibitor, a URAT1-inhibitor, and/or a xanthine oxidase inhibitor.~6. Positive test for hepatitis B, hepatitis C or HIV.~7. Use of any medications in the 2 weeks preceding first administration of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;
- Treatment B (Type: EXPERIMENTAL): Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).